Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (4): 438-444.doi: 10.12092/j.issn.1009-2501.2023.04.011

Previous Articles     Next Articles

Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells

LI Ruoning1 , GUO Zhanli1, WANG Yuan1, SUN Jianjun2   

  1. 1School of Pharmacy, Inner Mongolia Medical University, Hohhot 010100, Inner Mongolia, China; 2Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, Inner Mongolia, China
  • Received:2022-12-26 Revised:2023-02-11 Online:2023-04-26 Published:2023-05-17

Abstract:

Platelet-aggregation  receptor 1 (PEAR1) is a transmembrane receptor identified in 2005 and expressed mainly on platelets and endothelial cells. PEAR1 is a receptor protein that contacts platelets with each other and plays an important role in platelet activation and aggregation. Endothelial cells play an important role in maintaining vascular tone and vascular repair, and PEAR1 regulates the process of tumourigenesis and development by affecting their proliferation and associated neovascularisation. In recent years, PEAR1 has gradually been recognized as a potential target for anti-thrombotic drugs. This review focuses on elucidating the mechanisms of platelet endothelial aggregation receptor 1 and related signaling pathways in platelets and endothelial cells, and provides new ideas for the study of drug therapy for tumour-associated thrombosis.

Key words: platelet endothelial aggregation receptor 1, platelets, endothelial cells, signaling pathways, tumor thrombotic drugs

CLC Number: